Dr. Reddy's Laboratories Limited (BOM:500124)
India
· Delayed Price · Currency is INR | Market Cap | 1.04T |
| Revenue (ttm) | 334.26B |
| Net Income (ttm) | 56.80B |
| Shares Out | 832.37M |
| EPS (ttm) | 68.11 |
| PE Ratio | 18.39 |
| Forward PE | 20.46 |
| Dividend | 8.00 (0.66%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 41,837 |
| Average Volume | 61,811 |
| Open | 1,216.95 |
| Previous Close | 1,220.60 |
| Day's Range | 1,216.95 - 1,255.00 |
| 52-Week Range | 1,025.90 - 1,420.20 |
| Beta | 0.31 |
| RSI | 51.21 |
| Earnings Date | Jul 23, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Pharma sector stocks in focus: Citi flags competitive setback for Dr Reddy’s, Aurobindo in iron sucrose opportunity
Citi has highlighted a potential setback for Indian generic drugmakers Dr Reddy’s Laboratories and Aurobindo Pharma after the USFDA approved two generic versions of Iron Sucrose, developed by Viatris ...
Dr. Reddy’s Laboratorie gets EIR from USFDA for Telangana facility with VAI status
Dr. Reddy’s Laboratories has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. T...
Nifty top gainers and losers today, August 8: NTPC, Titan, Dr. Reddy’s Labs, HDFC Life among top performers
Indian equity markets ended in the red on August 8. The Nifty 50 slipped 232.85 points or 0.95% to close at 24,363.30, while the Sensex dropped 765.47 points or 0.95%, ending the session at 79,857.79....
Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt
Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock declines. Gokaldas Exports saw the steepest fall at 15.9%, with other text...
Dr. Reddy's: Needs To Invest $0.95 To Produce $1 Of New Revenues
Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy’s Laboratories, Adani Enterprises, Cipla and more
Indian equity markets ended Friday’s session (August 1) on a weak note, with both benchmark indices registering sharp declines. The BSE Sensex fell 585.67 points to settle at 80,599.91, while the NSE ...
Nifty 50 top losers today, July 31: Adani Enterprises, Tata Steel, Sun Pharmaceutical, Dr. Reddy and more
Indian stock markets closed in the red for the second consecutive session on July 31, with the Nifty 50 slipping below the 24,800 mark. The BSE Sensex declined 296.28 points to end at 81,185.58, while...
Why Dr. Reddy’s shares are down nearly 2% today? Explained
Shares of Dr. Reddy’s Laboratories Ltd dropped nearly 2% to ₹1,269.70 in early trade on Wednesday, reacting sharply to the overnight announcement by former U.S. President Donald Trump regarding the im...
Dr. Reddy’s Laboratories shares in focus as company sees double-digit sales growth for FY26
Dr. Reddy’s Laboratories shares were in the spotlight on Wednesday after the company’s management expressed confidence in achieving strong financial growth in FY26. As of 11:24 AM, the shares were tra...
This Indian pharma company sees a big opportunity in generic versions of weight-loss drugs
Dr. Reddy's Laboratories is betting big on a new wave of growth fueled by a global demand for weight-loss drugs.
Big Indian pharma is coming for Ozempic and Wegovy
Dr. Reddy's CEO Erez Israeli talks about the Indian pharma's plans to introduce a low-cost generic version of semaglutide - the active ingredient used in blockbuster weight-loss drugs Wegovy and Ozemp...
Dr. Reddy’s shares jump over 3% following Q1 results – Should you buy, hold or sell? Know More
Shares of Dr. Reddy’s Laboratories surged 3.06% to Rs 1,285.60 on Wednesday after the company reported its Q1 FY26 financial results. The stock touched an intraday high of Rs 1,287.90 and now commands...
Dr Reddy’s stock: CLSA, Jefferies recommend sell, Morgan Stanley says hold — here’s why
Top brokerages have delivered a mixed outlook on Dr. Reddy’s Laboratories following its Q1FY26 results. While Jefferies and CLSA retained their Underperform ratings citing concerns over U.S. business ...
Dr Reddy’s share: Morgan Stanley maintains equal-weight, sets Rs 1,298 target after Q1 margin pressure
Morgan Stanley has maintained its Equal-Weight rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,298 per share. The target indicates a modest upside from the current market price of ₹...
Dr Reddy’s share: Jefferies sees 12% downside after Q1 miss, cuts target to Rs 1,100
Jefferies has maintained its Underperform rating on Dr. Reddy’s Laboratories, lowering expectations with a target price of ₹1,100 per share. This implies a 12% downside from the current market price o...
Dr Reddy’s share: CLSA sees 10% downside, flags tapering US momentum and gRevlimid slowdown
CLSA has maintained its Underperform rating on Dr. Reddy’s Laboratories, assigning a target price of ₹1,120 per share, implying a 10% downside from the current market price of ₹1,248.00. The brokerage...
Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited 2026 Q1 - Results - Earnings Call Presentation
Dr Reddy’s PAT rises 2% despite record quarterly revenues in Q1FY26
Hyderabad: Despite clocking its highest-ever quarterly revenues during the first quarter ended June 30, pharma major Dr Reddy's Laboratories (DRL) on .
Dr. Reddy's Q1FY26 Financial Results
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #ConsolidatedFinancialResults--Dr. Reddy's Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2025.
Dr. Reddy’s to launch generic semaglutide in 87 countries: Bloomberg
India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 countries next year, the Indian drugmaker's CEO, Erez Israeli, said on Wed...
Dr. Reddy's GAAP EPS of $0.20, revenue of $997M misses by $3M
Dr Reddy’s Laboratories Q1 Results: Revenue jumps 11.4% YoY to Rs 8,545 crore, net profit marginally up
Dr. Reddy’s Laboratories kicked off the fiscal year on a solid note, posting its Q1 FY26 results with a healthy revenue increase but a slight dip in margins. The Hyderabad-based pharma giant reported ...
Q1FY26 results today: Infosys, Tata Consumer, Dr Reddy’s, SRF, Persistent among 40 companies to announce earnings on July 23
Investors will closely watch quarterly earnings from several key companies scheduled to report their Q1FY26 results today, July 23, 2025. Among the most anticipated are Infosys, Tata Consumer Products...